People: Synageva Biopharma Corp (GEVA.O)

Summary

Name	Age	Since	Current Position
Sanj Patel	43	2011	President, Chief Executive Officer, Director
Carsten Boess	45	2011	Chief Financial Officer, Senior Vice President
Eric Grinstead	55	2011	Senior Vice President - Commercial Operations
Anthony Quinn	50	2011	Senior Vice President, Chief Medical Officer
Felix Baker	44	2004	Independent Director
Stephen Biggar	41	2011	Independent Director
Stephen Davis	52	2007	Independent Director
Thomas Malley	43	2011	Independent Director
Barry Quart	56	2007	Independent Director
Matthew Osborne		2012	IR Contact

» Insider Trading

Biographies

Name	Description
Sanj Patel	Mr. Sanj K. Patel is President, Chief Executive Officer, Director of Synageva Biopharma Corp. since November 2, 2011, and prior to that time served as President and Chief Executive Officer and a director of Private Synageva since June 2008. He created the vision and strategy for Synageva, launching its focus on rare diseases and raising more than $200 million in capital, including taking Private Synageva public on the NASDAQ Global Market as a result of the Merger in November 2011. Mr. Patel has more than 20 years of experience in the pharmaceutical and biotech industries and brings a combination of scientific, clinical operations and business skills to Synageva. He joined Private Synageva from Genzyme Corporation (1999-2008) where most recently he was the head of U.S. Sales, Marketing and Commercial Operations for Genzyme Therapeutics’ Lysosomal Storage Disorder franchise and led the U.S. launch of Myozyme in addition to sales and marketing responsibility for Cerezyme, Fabrazyme and Aldurazyme. Previously, he held several cross-functional senior leadership roles at Genzyme, including Vice President, Clinical Research and Head of the Global Clinical Research Operations Council. He was responsible for clinical operations and development for all cross-business Genzyme products and was instrumental in the path to commercialization for several treatments. Notably, he led the Fabrazyme clinical operations team and development program for U.S. Food and Drug Administration approval in April 2003. Prior to Genzyme, Mr. Patel held roles in clinical research and commercial development with increasing levels of responsibility at Burroughs Wellcome, Hoechst Marrion Roussel and Fujisawa Pharmaceuticals. He obtained his BSc with Honors in Pure and Applied Biology (Biotechnology) from the University of the South Bank, London.
Carsten Boess	Mr. Carsten Boess is Chief Financial Officer, Senior Vice President of Synageva Biopharma Corp. since November 2, 2011. Prior to that time served Private Synageva in such capacity since May 2011. Mr. Boess is responsible for financial and strategic operations. He has more than 20 years of financial operations and management experience in the life sciences industry with diversified experience across a broad field of areas both in the U.S. and internationally. Prior to joining Private Synageva, Mr. Boess served in the roles of Chief Financial Officer and Vice President, International of Insulet Corporation, respectively (June 2006-2011) and has also served in the following capacities: Chief Financial Officer of Alexion Pharmaceuticals, Inc., Executive Vice President of Finance for Serono, Inc. and Vice President Finance, International Operations, Novo Nordisk. Mr. Boess has international experience having served as head of finance of companies in the U.S., Denmark, China, Switzerland, and France. He also headed the expansion of Insulet’s business internationally in the role of Vice President, International. Mr. Boess earned a Bachelor’s and Master’s degree in economics and finance from the University of Odense, Denmark.
Eric Grinstead	Mr. Eric Grinstead is Senior Vice President - Commercial Operations of Synageva Biopharma Corp. since November 2, 2011. Prior to that time served Private Synageva in such capacity since July 2009. He brings over 20 years of experience in the biopharmaceutical industry with responsibilities spanning operations, market access, sales, marketing, reimbursement and government affairs at Alexion, Genzyme, Amgen and GlaxoSmithKline plc. More specifically, his experience includes pricing, health economics, distribution, channel and payor segments, specialty networks, policy, patient and alliance management, patient assistance programs and commercial operations for rare and ultra-rare diseases in both the U.S. as well as ex-U.S. regions. Prior to joining Private Synageva in 2009, Mr. Grinstead was at Alexion from September 2006 to July 2009, where as a member of the management team, his efforts with the commercial functions helped to support the launch of Soliris. At Genzyme, he was responsible for the patient and product services group for the lysosomal storage diseases franchise. Before Genzyme, Mr. Grinstead worked for Amgen with responsibilities for brand economics in rheumatology and anemia business units and state government affairs for all brands. Mr. Grinstead earned a B.A. (cum laude) from Westmont College.
Anthony Quinn	Mr. Anthony G. Quinn, MBChB (M.D.), Ph.D., FRCP is Senior Vice President, Chief Medical Officer of Synageva Biopharma Corp. since November 2, 2011. Prior to that time served Private Synageva in such capacity since August 2009. He joined Private Synageva from Roche where, from September 2004 until joining Private Synageva, he was Vice President and Global Head of Clinical Research & Exploratory Development for Inflammation. While at Roche, Dr. Quinn managed programs in rheumatology and respiratory indications in exploratory development, and biomarker and translational medicine activities in the late clinical and registration phase for MabThera™/Rituxan™, Actemra™ and Ocrelizumab. Dr. Quinn joined Roche in 2005 to build the translational medicine and exploratory development capabilities at the site across a broad range of therapeutic areas including CNS, virology and inflammation. Prior to joining Roche he was Director of Experimental Medicine at AstraZeneca, Charnwood in the UK, and before that he was Professor of Dermatology at Barts & The London School of Medicine, London, England. He has authored or co-authored more than 50 peer-reviewed journal articles, book chapters, reviews and editorials, predominantly on Hedgehog signaling and the molecular biology of non-melanoma skin cancer. He received his Bachelor of Medical Science with First class honors and his MBChB (M.D.) with commendation from the University of Dundee, UK. Dr. Quinn trained in internal medicine, dermatology and molecular biology at the University of Newcastle upon Tyne and was also awarded his Ph.D. there. He completed a postdoctoral fellowship at University of California, San Francisco, and is a fellow of the Royal College of Physicians London.
Felix Baker	Dr. Felix J. Baker, Ph.D. is an Independent Director of Synageva BioPharma Corp. since April 2004. He is a director of Private Synageva since October 2000, and Chairman of the Board of Private Synageva since 2003, and serves as Chairman of the Board of the Company today. Dr. Baker is a Managing Member of Baker Bros. Advisors, LLC, which he and his brother, Mr. Julian Baker, founded in 2000. Dr. Baker’s firm manages Baker Brothers Investments, a family of long-term investment funds for university endowments and foundations, which are focused on publicly traded life sciences companies. Dr. Baker’s career as a fund manager began in 1994 when he co-founded a biotechnology investing partnership with the Tisch Family. Dr. Baker holds a B.S. and a Ph.D. in Immunology from Stanford University, where he also completed two years of medical school. In addition to Synageva, Dr. Baker is a director of Ardea Bioscience, Inc. and Seattle Genetics, Inc., both of which are publicly traded biotechnology companies. Dr. Baker was previously a director of AnorMED Inc., Conjuchem Inc. and Neurogen Corporation, which were publicly traded companies during Dr. Baker’s service.
Stephen Biggar	Mr. Stephen R. Biggar, M.D., Ph.D. is Independent Director of Synageva Biopharma Corp. since November 2, 2011. Prior to that time served as a director of Private Synageva since May 2004. Since October 2006, Dr. Biggar has served as a Partner at Baker Brothers Investments, a family of long-term investment funds for university endowments and foundations, which are focused on publicly traded life sciences companies. From April 2002 to October 2006 he served as Principal with Baker Brothers Investments which he had joined as an Associate in April 2000. Prior to joining Baker Brothers, Dr. Biggar received an M.D. and a Ph.D. in Immunology from Stanford University and received a B.S. degree in Genetics from the University of Rochester. Dr. Biggar also serves as a director for BioCryst Pharmaceuticals, Inc., a publicly traded biotechnology company.
Stephen Davis	Mr. Stephen R. Davis is Independent Director of Synageva BioPharma Corp., since June 2007. Mr. Davis is currently the Chief Operating Officer of Ardea Biosciences, Inc. Prior to joining Ardea in 2010, Mr. Davis served as President and Chief Executive Officer of Neurogen Corporation, which was acquired by Ligand Pharmaceuticals in December 2009. Prior to becoming Chief Executive Officer in February 2008, Mr. Davis served as Neurogen’s Chief Operating Officer beginning in April 2005 and Executive Vice President and Chief Business Officer from September 2001 through April 2005. Mr. Davis was also a director of Neurogen until December 2009. Mr. Davis joined Neurogen in 1994 as Vice President of Finance and Chief Financial Officer. From 2010 to 2011 Mr. Davis served on the Board of Directors A.P. Pharma. A.P. Pharma is and Neurogen, prior to its acquisition by Ligand, was a publicly held company. From 1990 through June 1994, Mr. Davis was a corporate and securities attorney at Milbank, Tweed, Hadley& McCloy LLP. Previously, Mr. Davis practiced as a Certified Public Accountant with Arthur Andersen & Co. Mr. Davis received his B.S. in Accounting from Southern Nazarene University and a J.D. from Vanderbilt University.
Thomas Malley	Mr. Thomas R. Malley is Independent Director of Synageva Biopharma Corp. since November 2, 2011, and prior to that time served as a director of Private Synageva since October 2006. Since May 2007, Mr. Malley has served as President of Mossrock Capital, LLC, a private investment firm. From December 1998 to May 2007, Mr. Malley served with Janus Mutual Funds, including as Vice President and Portfolio Manager for the Janus Global Life Sciences Fund. From April 1991 to December 1998, Mr. Malley served as an equity analyst for Janus Mutual Funds. Mr. Malley previously served as a director of Cougar Biotechnology, Inc. from 2007 to 2009, which was a publicly traded company until Johnson & Johnson acquired the company in 2009. Mr. Malley is also a director of Puma Biotechnology, Inc., a publicly traded biotechnology company. Mr. Malley holds a B.S. in Biology from Stanford University.
Barry Quart	Dr. Barry D. Quart, Pharm.D., is Independent Director of Synageva BioPharma Corp., since June 2007. Since December 2006, Dr. Quart has served as President and Chief Executive Officer of Ardea Biosciences, Inc. He has also been a director of Ardea since December 2006. From 2002 until December 2006, Dr. Quart was President of Napo Pharmaceuticals, Inc. Dr. Quart was also a director of Napo from April 2002 to December 2006. Prior to Napo, Dr. Quart was Senior Vice President, Pfizer Global Research and Development and the Director of Pfizer’s La Jolla Laboratories. Prior to Pfizer’s acquisition of the Warner-Lambert Company, Dr. Quart was President of Research and Development at Agouron Pharmaceuticals, Inc., a division of the Warner-Lambert Company, since 1999. Prior to joining Agouron in 1993, Dr. Quart spent over 10 years at Bristol-Myers Squibb in both Clinical Research and Regulatory Affairs. Dr. Quart holds a Pharm.D. from the University of California, San Francisco.
Matthew Osborne

Basic Compensation

Name	Fiscal Year Total
Sanj Patel	3,127,160
Carsten Boess	1,091,660
Eric Grinstead	--
Anthony Quinn	1,263,770
Felix Baker	--
Stephen Biggar	--
Stephen Davis	--
Thomas Malley	--
Barry Quart	--
Matthew Osborne	--

As Of 30 Dec 2011

Options Compensation

Name	Options	Value
Sanj Patel	0	0
Carsten Boess	0	0
Eric Grinstead	0	0
Anthony Quinn	16,185	2,428
Felix Baker	0	0
Stephen Biggar	0	0
Stephen Davis	0	0
Thomas Malley	0	0
Barry Quart	0	0
Matthew Osborne	0	0

Insider Trading

Name	Shares Traded	Price
PATEL SANJIV K	14,731	$1.70
PATEL SANJIV K	40,352	$40.48
PATEL SANJIV K	25,621	$0.95
PATEL SANJIV K	6,105	$0.95
PATEL SANJIV K	23,543	$0.95
PATEL SANJIV K	29,648	$40.89
PATEL SANJIV K	21,695	$0.95
PATEL SANJIV K	21,695	$49.49
PATEL SANJIV K	9,910	$50.11
PATEL SANJIV K	9,910	$0.95
PATEL SANJIV K	21,931	$0.95
PATEL SANJIV K	1,200	$51.64
PATEL SANJIV K	2,151	$50.72
PATEL SANJIV K	18,580	$50.12
PATEL SANJIV K	9,464	$0.95
PATEL SANJIV K	4,358	$52.55
PATEL SANJIV K	1,500	$53.37
PATEL SANJIV K	10,206	$51.09
PATEL SANJIV K	400	$54.44
PATEL SANJIV K	7,000	$0.95
GOLDBERG MARK ALAN	619	$54.92
GOLDBERG MARK ALAN	3,091	$0.95
GOLDBERG MARK ALAN	3,797	$54.21
GOLDBERG MARK ALAN	1,325	$0.95
GOLDBERG MARK ALAN	2,704	$50.39

» Full list on Insider Trading

People: Synageva Biopharma Corp (GEVA.O)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: